Sunday , September 23 2018
Home / Letter From The Editor / Letter from the Editor: New GLP-1 Article

Letter from the Editor: New GLP-1 Article

Dec 10, 2011

We have been sharing a lot of information about native GLP-1 and GLP-1 analogs, and how these compounds work to control glucose levels in our patients. Lately there has been a lot of press concerning the possible cardiovascular benefits of using these analogs in our patients.

We’ve been able to secure a new research paper and had our current LECOM Doctor of Pharmacy Candidate, Vannessa Mellott, review and enhance the paper for you. Check out Part 1 of GLP-1 Agonist-based Therapies: An Emerging New Class of Antidiabetic Drug With Potential Cardioprotective Effects.

Articles addressing the negative effects of low testosterone are usually focused on sexual dysfunction in diabetes patients, and many times our older patients have lower levels but we tend not to worry about them. This week’s Item #11, Low Testosterone Affects Insulin Sensitivity, looks at how low testosterone levels can affect insulin sensitivity and why more of our patients should be tested.



NEW CME available! 13 AMA PRA Category 1 Credits are now available from CardioCareLive. See our CME page for all of CardioCareLive’s enduring CME available. December 11, 7PM ET on CNBC

Topics: dLife explores how diabetes can impact your love life, and what you can do about it. Plus, a mouthwatering soufflé that anyone can make from the dLife kitchen. Sundays on CNBC at 7 PM ET, 6 PM CT, and 4 PM PT. Catch up on

Please answer this week’s poll: Where is your diabetes education practice primarily based?

Vote in and then see results from previous polls here.

We can make a difference!

Check out this week’s “Test Your Diabetes Knowledge” question!

Dave Joffe, Editor-in-chief